Logo

Apalutamide in nmCRPC: QOL as Good as ADT Alone

ARTICLES

Apalutamide in nmCRPC: QOL as Good as ADT Alone


MEDSCAPE
PUBLISHED: 27 MARCH 2018


New results suggest that health-related quality of life (HRQOL) is good with the new-generation antiandrogen inhibitor apalutamide (Erleada, Janssen), which recently became the first agent to be approved for use in men with nonmetastatic castrate-resistant prostate cancer (nmCRPC).

explore_now-footer.png

Published

March 27, 2018

Categories

Oncology
CP-202103